Dual inhibition of BTLA and PD-1 can enhance therapeutic efficacy of paclitaxel on intraperitoneally disseminated tumors

BACKGROUND: Expression of immune checkpoints in the tumor microenvironment is one mechanism underlying paclitaxel (PTX) chemoresistance. This study aimed to investigate whether the addition of checkpoint blockade to PTX can improve the therapeutic efficacy against apparently disseminated intraperito...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Wei-Zen, Lin, Han-Wei, Chen, Wan-Yu, Chien, Chung-Liang, Lai, Yen-Ling, Chen, Jung, Chen, Yu-Li, Cheng, Wen-Fang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10357656/
https://www.ncbi.nlm.nih.gov/pubmed/37463789
http://dx.doi.org/10.1136/jitc-2023-006694

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10357656/
https://www.ncbi.nlm.nih.gov/pubmed/37463789
http://dx.doi.org/10.1136/jitc-2023-006694

Ejemplares similares